文献速递免疫规划传染病防控与疫情报告

突尼斯普及乙肝疫苗接种20年后疫苗效果观察性研究

Observational study of vaccine effectiveness 20 years after the introduction of universal hepatitis B vaccination in Tunisia.
PubMed 文献 · Vaccine · 2018-08-23

该研究基于2015年突尼斯全国住户横断面血清学调查,采用两阶段随机抽样,估计乙肝表面抗原全国点患病率为1.7%(95%CI [1.6-1.9%]),疫苗效果为88.6%(95%CI [81.5-93.0%]),20岁以下人群疫苗效果96.1%(95%CI [70.1-99.5%])高于20岁以上人群59.0%(95%CI [32.0-75.3%]),结论认为突尼斯已归为低流行国家。

要点

  • 全国乙肝表面抗原点患病率为1.7%(95%CI [1.6-1.9%]),中心区和南部地区较高。
  • 总体疫苗效果88.6%(95%CI [81.5-93.0%]),20岁以下人群达96.1%(95%CI [70.1-99.5%])。
  • 20岁以上人群疫苗效果59.0%(95%CI [32.0-75.3%]),低于20岁以下人群。

核心结论

  • 乙肝表面抗原患病率较既往估计下降,自1995年引入疫苗接种使突尼斯归为低流行国家。

研究设计与样本

  • 2015年开展全国住户横断面血清学调查,采用两阶段抽样从随机选取的地区收集数据,使用标准化预试验问卷并检测乙肝病毒感染的血清学标志物。

主要发现

  • 全国乙肝表面抗原点患病率为1.7%(95%CI [1.6-1.9%])。
  • 中心区和南部地区患病率最高,分别为2.3%(95%CI [2.0-2.7%])和2.2%(95%CI [1.8-2.8%])。
  • 总体疫苗效果为88.6%(95%CI [81.5-93.0%])。
  • 20岁以下人群疫苗效果为96.1%(95%CI [70.1-99.5%]),高于20岁以上人群的59.0%(95%CI [32.0-75.3%])。
  • 高流行区疫苗效果为85.6%(95%CI [65.8-93.9%]),中低流行区为89.1%(95%CI [80.3-94.0%])。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objectives of this study were to estimate the national prevalence of hepatitis B infection in Tunisia using data from a nationwide survey, to compare results with those obtained in 1996 survey and to evaluate the impact of vaccination twenty years after its introduction. METHODS: A National household-based cross sectional and serological survey was undertaken in 2015 from randomly selected districts using two-stage sampling. Data collection was performed using standardized and pretested questionnaires and collected blood samples were tested for markers of hepatitis B virus infection. RESULTS: National point prevalence of Hepatitis B surface antigen was 1.7% (95% CI [1.6-1.9%]). The highest prevalence was found in the Center and South regions with respectively 2.3% (95% CI [2.0-2.7%]) and 2.2% (95% CI [1.8-2.8%]). Vaccine effectiveness (VE) was 88.6% (95% CI [81.5-93.0%]) and was higher among population aged less than 20 years 96.1% (95% CI [70.1-99.5%]) than those aged more than 20 years 59.0% (95% CI [32.0-75.3%]). VE was 85.6% (95% CI [65.8-93.9%]) is hyper-endemic areas and 89.1% (95% CI [80.3-94.0%]) in meso-endemic and hypo-endemic areas. CONCLUSIONS: The prevalence of Hepatitis B surface antigen decreased compared to previous estimations and classify Tunisia as a low endemic country as result to the introduction of vaccination since 1995.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ben Hadj M, Bouguerra H, Saffar F, et al. Observational study of vaccine effectiveness 20 years after the introduction of universal hepatitis B vaccination in Tunisia. Vaccine. 2018. PMID: 30145100. doi:10.1016/j.vaccine.2018.08.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。